Edarbyclor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(1 year, 7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(1 year, 3 months from now)

US9066936 AZURITY Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Mar, 2028

(4 years from now)

US9169238 AZURITY Solid pharmaceutical composition
Feb, 2030

(6 years from now)

US9387249 AZURITY Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
Jul, 2031

(7 years from now)

Edarbyclor is owned by Azurity.

Edarbyclor contains Azilsartan Kamedoxomil; Chlorthalidone.

Edarbyclor has a total of 5 drug patents out of which 0 drug patents have expired.

Edarbyclor was authorised for market use on 20 December, 2011.

Edarbyclor is available in tablet;oral dosage forms.

Edarbyclor can be used as treatment of hypertension.

The generics of Edarbyclor are possible to be released after 01 July, 2031.

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension


How can I launch a generic of EDARBYCLOR before it's drug patent expiration?
More Information on Dosage

EDARBYCLOR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic